The use of abciximab (c7E3 Fab) as a therapeutic adjunct to transluminal coronary balloon angioplasty - systematic review
Conseil d'Evaluation des Technologies de la Sante du Quebec
Record ID 31999008423
English, French
Authors' objectives:
This report determines whether the use of abciximab with angioplasty leads to a reduction in the frequency of myocardial infarction, the need for revascularization procedures or postangioplasty mortality, as well as in the late coronary reocclusion rate. It also examines the extent of the health benefits and the direct cost to the health-care system associated with this use of abciximab.
Authors' recommendations:
There is clear evidence that use of abciximab with angioplasty will lower the myocardial infarction rate and the need for revascularization procedures, which are complications associated with angioplasty.
The greatest effect will be seen in procedures where the event rates (myocardial infarction and revascularization) are highest.
Confident estimates of the cost and health benefits to be expected from the use of abciximab in Quebec are not possible because of uncertainty as to the rate of myocardial infarction and revascularization events at present associated with angioplasty.
Although each myocardial infarct prevented may eventually result in some prolongation of life, there are still no conclusive data supporting such a hypothesis. Thus, estimates of cost effectiveness in terms of dollars per year of life cannot be used with confidence to directly compare the use of abciximab with other health care interventions.
These estimates are based on only four trials. However, until more trials are completed these provide the best available evidence on which to base policy decisions. The field is evolving and new evidence may soon necessitate revision of these conclusions.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.aetmis.gouv.qc.ca/
Year Published:
1998
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Angioplasty, Balloon
- Costs and Cost Analysis
- Myocardial Infarction
- Platelet Aggregation Inhibitors
- Thrombosis
Contact
Organisation Name:
Conseil d'Evaluation des Technologies de la Santé du Québec
Contact Address:
Conseil d'Evaluation des Technologies de la Santé du Québec, 2021, avenue Union, #1040, Montréal, Québec H3A S29, Canada. Tel: 514-873-2563; FAX: 514-873-1369
Contact Name:
aetmis@aetmis.gouv.qc.ca
Contact Email:
aetmis@aetmis.gouv.qc.ca
Copyright:
Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.